Purpose Activating genetic changes in the phosphatidylinositol-3-kinase (PI3K) signaling pathway are found in over half of invasive breast cancers (IBCs). Previously, we discovered numerous hotspot PIK3CA mutations in proliferative breast lesions. Here, we investigate the spatial nature of PI3K pathway signaling and its relationship with PI3K genotype in breast lesions. Methods We identified PI3K phosphosignaling network signatures in columnar cell change (CCL), usual ductal hyperplasia (UDH), ductal carcinoma in situ (DCIS), and IBC in 26 lesions of known PIK3CA genotype from 10 human breast specimens using a hyperspectral-based multiplexed tissue imaging platform (MTIP) to simultaneously quantitate PI3K/MAPK pathway targets (pAKT473, pAKT308, pPRAS40, pS6, and pERK) in FFPE tissue, with single-cell resolution. Results We found that breast lesional epithelia contained spatially heterogeneous patterns of PI3K pathway phosphoprotein signatures, even within microscopic areas of CCL, UDH, DCIS, and IBC. Most lesions contained 3-12 unique phosphoprotein signatures within the same microscopic field. The dominant phosphoprotein signature for each lesion was not well correlated with lesion genotype or lesion histology, yet samples from the same patient tended to group together. Further, 5 UDH/CCL lesions across different patients had a common phosphosignature at the epithelial-stromal interface (possible myoepithelial cells) that was distinct from both the adjacent lesional epithelium and distinct from adjacent stroma. Conclusion We present the first spatial mapping of PI3K phosphoprotein networks in proliferative breast lesions and demonstrate complex PI3K signaling heterogeneity that defies simple correlation between PIK3CA genotype and phosphosignal pattern.
Introduction
Genomic study of breast cancer has greatly increased our knowledge of its molecular landscape and complexity. Numerous studies have demonstrated that well over half of breast cancers have genetic changes in components of the phosphatidylinositol-3-kinase (PI3K) signaling cascade, predicted to result in pathway activation [1] [2] [3] [4] [5] . These genomic changes include amplification, mutation, or activation of receptor tyrosine kinases (HER2, EGFR), mutation or amplification of the catalytic subunit (PIK3CA), mutation or amplification of AKT1, or loss of inhibition, impacting the PIK3R1 regulatory subunit, or phosphatase and tensin homolog (PTEN) function [2] [3] [4] [5] . Considerable efforts have been directed to pharmacologic targeting of aberrant PI3K pathway activity [2] [3] [4] 6] .
Activating 'hotspot' point mutations in PIK3CA are present in about 25 % of invasive breast cancers and are even further enriched in luminal-A cancers including invasive lobular carcinoma [1] [2] [3] [4] [5] . Accumulating data from a number of different studies show that concurrent invasive and in situ breast carcinoma (ductal carcinoma in situ, DCIS) in the same patient frequently harbor identical PIK3CA mutations [7] [8] [9] [10] [11] . This observation fits the prevailing notion of DCIS as a direct precursor of invasive breast cancer and furthers the concept of activating PIK3CA mutations as a potential 'driver' of breast carcinogenesis. Further, we and others have recently shown that PIK3CA mutations are present in both 'benign' and 'atypical' proliferative breast lesions [11] [12] [13] . However, the PIK3CA mutation status of these proliferative breast lesions was frequently different than that of concurrent invasive carcinoma sampled from the same tissue specimen. For example, in ten patients with PIK3CA wild-type (WT) carcinoma each had PIK3CA exon 20-mutated proliferative lesions present in the same breast tissue specimen [11] . Activating PIK3CA mutations have been shown to evoke downstream PI3K network signaling that fuels cellular transformation and cancer growth in vitro, but their in vivo activity within lesional tissue is more difficult to establish [14, 15] , in light of intra-network inhibitory feedback loops or inter-network cross-talk [2-4, 16, 17] .
Given the high prevalence of mutations and the potential impact of PIK3CA mutation on downstream signaling in breast epithelial proliferation/neoplasia, we sought to capture the spatial nature of PI3K network signaling and its relationship with PIK3CA mutations in proliferative breast lesions. To do this, we used MTIP, a new multiplexed hyperspectral tissue imaging platform [18] to identify and map the location of phosphorylated PI3K network signaling nodes [pAKT1 (308, 473), pPRAS40, pS6, and pERK] and identify distinct PI3K network signatures. We examined these PI3K/MAPK network signatures in relation to PIK3CA genotype, histologic lesion type, and other spatial features.
Methods

Histologic specimens and genotyping
Tissue specimens of known genotype were derived from our previous study of breast precursor lesions, with an IRB-approved protocol [11] . Briefly, these specimens were fixed in formalin, processed, and paraffin-embedded (FFPE), using standard clinical practice methods. Breast lesions of interest on H&E-stained glass slides were identified by a breast pathologist (MLT), and 1-to 2-mm cores were taken from the corresponding tissue block. Cored tissue was re-embedded, the histologic diagnosis confirmed, and paraffin shavings were used for DNA extraction. DNA was screened for a large panel of hotspot mutations as previously described, including 58 substitutions in 34 codons of the PIK3CA gene; point mutations were confirmed by sequencing [11] . From this cohort, 29 lesions from 10 patients were selected for image analysis, based on the availability of multiple lesions (up to 4) with different PIK3CA mutations from the same patient ( Table 1) .
Multiplexed phosphoprotein staining and imaging FFPE lesion specimens were cut as 4-lm-thick unstained serial sections from the same tissue block previously used for genotyping. One level was stained by hematoxylin and eosin (H&E); another was used for multiplexed imaging (within 24-48 microns). Lesion sections from each patient were arranged on a single slide. Immunostaining was performed on FFPE specimens using a Benchmark XT autostainer (Ventana Medical Systems, VSMI, Tucson AZ), as reported earlier [18] . All FFPE specimens were subjected to automated deparaffinization in EZprep buffer (VMSI Cat# 950-102) followed by cell conditioning with the CC1 buffer (VMSI Cat#950-124) for 90 min prior to antibody incubation. FFPE specimens were incubated with a cocktail of hapten-conjugated primary antibodies (pS6:BF, pAKT S473:DIG, pPRAS40:NP, pERK 1/2:NCA, pAKT T308:DNP at 5, 15, 20, 30, 12.5 lg/mL) at 37°C for 32 min. Following the primary antibody incubation step, the samples were incubated with secondary anti-hapten antibody quantum dot (QD) conjugates (anti-BF:QD525, anti-DIG:QD565, anti-NP:QD605, anti-NCA:QD625, anti-DNP:QD655 at 40, 50, 70, 40, and 30 nM concentrations, respectively) at 37°C for 32 min [18] . All primary antibodies were purchased from Cell Signaling Technologies (Danvers, MA, USA). Anti-hapten-specific secondary mouse monoclonal antibodies were conjugated to quantum dots (Life Technologies, Eugene, OR, USA), using standard bioconjugation methods [19] . Following automated staining with antibodies, the samples were dehydrated in ethanol series, followed by xylene, and mounted using Cytoseal 60 (Thermo Scientific) in preparation for spectral imaging.
Image acquisition and analysis
We mapped PI3K/MAPK network signaling in breast lesions using MTIP, a multiplexed, spectral imaging platform developed for precise, quantitative spatial mapping of phosphosignaling in FFPE tissue [18] . Regions of interest were selected within pathologist-identified breast lesions and spectrally acquired and unmixed. The signaling activity for each phosphoprotein species was quantified from the pixel intensity of unmixed channels. Pixel values that were 1 percent of the brightest signal in the field of view were excluded to remove nonrelevant pixel contributions from unstained areas, and pixels above 95 % of the maximum intensity were clamped at the 95 % intensity level to remove spurious contributions from hot pixels. Identification of signaling network signatures was performed using mean shift algorithms to extract segmented groups of similar signaling patterns; these algorithms are tolerant of irregularly shaped distributions and functions without a priori assumptions of a fixed number of distinct phosphosignaling signatures or discrete cut-off points for establishing phosphosignaling signature uniqueness. Standard, nonparametric hierarchical analysis was employed to rank similarities by Euclidean distances among predominant PI3K/MAPK network signatures (top 1-2 signatures occupying the greatest area of tissue) and displayed in dendrogram format (Matlab). 
Results
We analyzed twenty-nine breast lesions of known PIK3CA mutation status from ten patients (Table 1 ). This cohort focused on patients with proliferative lesions (usual ductal hyperplasia-UDH, columnar cell lesion-CCL) and invasive or in situ carcinomas of different PIK3CA genotypes. The study group included CCL/UDH, n = 12, atypical ductal hyperplasia, n = 1, carcinoma in situ, n = 4 (3 DCIS, 1 lobular, LCIS), invasive carcinoma, n = 11 (9 ductal, 2 lobular), and metastatic lobular carcinoma in one lymph node. Multiplexed phosphoantibody staining and spectral imaging of phosphoactivated protein species (pAKT473, pAKT308, pPRAS40, pS6, and pERK) was performed on the cohort (see ''Methods'' section). Staining and imaging was successful in 26 of 29 specimens. The phosphosignaling intensity of each antibody was quantified within the regions of interest, and PI3K/MAPK network signatures were identified as distinct patterns of reactivity across all 5 phosphoprotein signaling species (Fig. 1) . Pseudocolored maps were generated to show the location of distinct phosphoprotein signatures in lesion tissue (Fig. 1) .
Epithelial heterogeneity
Multiplexed imaging and identification of PI3K/MAPK phosphoprotein network signatures within breast tissue showed that stromal areas and epithelium differed; epithelia showed higher levels of phosphoactivation in all 5 phosphoprotein species compared to the surrounding stromal areas (e.g., cluster 1 plots and white-coded clusters, Fig. 1a, b) . Interestingly, multiplexed imaging also revealed considerable diversity of PI3K pathway signatures within breast epithelium (each signature characterized by unique patterns of activation of each of 5 phosphoprotein species). As many as 12 distinct network signatures were identified within the small areas of lesional epithelium, while most samples had 3-4 or more distinct signatures spatially mapped (example of CCL and UDH, Fig. 1a, b) . These images also show varied spatial patterns of signaling and heterogeneous grouping of subpopulations of cells with distinct signaling (e.g., clusters 3, 5, 12, Fig. 1a , and clusters 3 and 4, Fig. 1b ).
PI3K/MAPK network signatures at the epithelialstromal interface
Inspection of phosphoprotein signaling maps revealed a distinct PI3K/MAPK network signature at the epithelialstromal interface in 5 noninvasive lesions from different patients (4 columnar cell lesions, some accompanied by usual or atypical hyperplasia, and one usual ductal hyperplasia). Review of serial sections stained with H&E showed prominence of the myoepithelial cell layer in the 4 columnar cell lesions (arrows in H and E, green cluster in pseudocolor map, and cluster 3 in plot, Fig. 1b) . The network signature at this epithelial-stromal cellular interface was characterized by moderate levels of pERK and pAKT T308. The adjacent lesional epithelium had relatively higher levels of pAKT T308 compared to the interface signature, yet had moderate levels of pERK (Figs. 1b and 2).
Clustering of PI3K/MAPK network signatures analyzed by PIK3CA genotype and lesion type
We investigated similarities between PI3K/MAPK network signatures and their relationship to genotype and histologic type across all imaged breast lesions by computing Euclidean distances. Dendrograms showing similarities and distances, and heatmaps showing the relative intensity of each phosphoprotein were constructed using the dominant network signature for each lesion (signature occupying the largest area of each lesion -1 or rarely 2 network signatures each; Fig. 2 ). The analysis revealed that lesions of the same PIK3CA genotype from different patients did not cluster together, indicating that PIK3CA genotype did not correlate in a simple manner with specific PI3K pathway signatures. For example, lesions with the PIK3CA exon 20 H1047R mutation, coded in yellow in the rightmost column of Fig. 2 , were spaced throughout the dendrogram tree. Furthermore, lesions of the same histology did not cluster together. For example, the bottom portion of the dendrogram contains a branch that contains IDC, DCIS, and columnar cell lesions (some mixed with UDH and ADH) from patients 21R, 44 and 4, respectively. We did, however, find similarity in Fig. 2 ). In summary, breast lesions contain a diverse set of unique PI3K/MAPK phosphosignatures irrespective of PIK3CA genotype and histologic type.
Discussion
We have characterized PI3K/MAPK network activation in a cohort of premalignant and malignant breast lesions of known PI3KCA genotype. The data show that even small breast lesions contain a wide diversity of unique PI3K network signatures. Moreover, these networks are distributed heterogeneously through the epithelium. Lesion genotype is not directly related to a predominant PI3K/ MAPK network signature. However, we identified a unique phosphoprotein signature at the epithelial-stromal interface that appears to be common across some proliferative CCL breast lesions with morphologically prominent myoepithelial cells. Genomic heterogeneity within malignant tumors has gained considerable attention recently and is postulated to account for some degree of therapy resistance [4, 10] . Classic studies demonstrated genomic differences between metastases in renal cell carcinoma [20] , and a growing body of data is revealing genetic and protein expression heterogeneity within breast primary carcinomas, and between primary and metastatic carcinoma, including PIK3CA genotype [4, 10, [21] [22] [23] [24] [25] . We previously demonstrated the spatial heterogeneity of PI3K phosphoprotein signatures in invasive breast cancers. In the present study, we show that microscopic foci of proliferative and precursor breast lesions also contain a diversity of unique PI3K signaling signatures, with heterogeneous spatial localization across the tissue. Mathematical algorithms delineated up to 12 unique PI3K pathway phosphoprotein signatures within microscopic fields of breast epithelial proliferations; most lesions contained 3-4 signatures. While UDH is a morphologically heterogeneous lesion as compared to in situ breast carcinoma, [26, 27] , our multiplexed spatial mapping showed phosphosignaling heterogeneity within small UDH, DCIS, and other breast lesions.
Our results show not only the range of activated phosphoprotein species in each lesion, but also the spatial relationships of these multiple downstream phosphorylated (activated) species within the same signaling cascade. Phosphofunctional signaling pathways in proliferative breast lesions have not been previously mapped, to our knowledge.
Our study group included breast lesions of different PIK3CA genotype in order to investigate the correlation between PIK3CA mutations and PI3K phosphoprotein signaling. Our analysis of phosphoprotein signatures in 26 breast lesions demonstrated that lesions of the same PIK3CA genotype did not cluster together (Fig. 2) . For this study, genotype was established by sequencing DNA extracted from serial sections of lesional tissue, which does not preserve spatial information. Application of multiplex PI3K pathway imaging, together with PIK3CA mutationspecific antibodies, would allow for more precise mapping of genotype-phenotype associations (or lack thereof), as genotype may also theoretically be heterogeneous in proliferative lesions [28, 29] . Unfortunately, such PIK3CA antibodies are not currently available, and we were unable to correlate with PIK3R1, PTEN genotype, or other pathway elements that could also influence signaling. Further, we did not observe clustering by histologic type of lesion (proliferative vs. malignant for instance). Instead, different lesions from the same patient tended to cluster nearby. This observation could derive from differences in hormonal status or other systemic or field effects between patients. As shown in Table 1 , patient age, and thus pre-menopausal/post-menopausal status, was highly variable across the study group. All of the lesions from an individual patient were combined on a single slide for staining and imaging (lesions from patients 23 and 26 were combined on a slide, likewise 29 and 41). Based on reproducibility data from our laboratory [18] , it is unlikely that variability in staining would account for the observed clustering within patients. We cannot exclude the possibility, however, that pre-analytic factors played a role. This retrospective study included historical specimens that preceded the recording or controlling of ischemic time in our laboratory; specimen fixation times are listed in Table 1 and are generally within ASCO/CAP guidelines [30] . Despite this caveat, the specimens maintained a robust spectrum of phosphoprotein signatures.
The observed patterns of phosphoprotein activation were spatially complex and seemingly 'randomly' distributed within breast epithelial lesions. Nevertheless, there was one recurring PI3K signature, which was seen in 5 proliferative, noninvasive breast lesions at the epithelialstromal interface (Figs. 1b and 2 ). This particular signature was characterized by moderate levels of pERK and pAKT T308, with pAKT T308 lower than the adjacent epithelium. Interestingly, unsupervised clustering placed the epithelialstromal interface signature from different patients fairly closely together (Fig. 2) . We also noted that myoepithelial cells were prominently seen between the epithelium and basement membrane/stroma in lesions with an interface signature, which could potentially represent a myoepithelial signature. The role of epithelial-stromal interactions and epithelial-myoepithelial-stromal interactions in cancer progression is increasingly recognized, and this interface phosphoprotein signature offers an avenue for further investigation. Analysis of additional lesions and multiplex staining incorporating myoepithelial cell markers (such as p63, calponin, smooth muscle myosin heavy chain) would be a next step to investigate this hypothesis [31, 32] .
In conclusion, we demonstrate a heterogeneous and complex PI3K phosphoprotein signature in premalignant and malignant breast lesions, without clear PIK3CA genotypic correlation. These findings support the notion that protein expression and pathway activation should be tested in addition to genotype, in designing precision medicine treatments for breast cancer [4] . We have illustrated the importance of spatial mapping and the potential of quantitative multiplexed image techniques to enrich the study of breast neoplasia in subsequent larger studies.
